Johnson & Johnson (NYSE:JNJ) Submits sNDA For Schizophrenia Drug CAPLYTA® To FDA
unknown📝 Article Content
Johnson & Johnson (NYSE:JNJ) submitted a supplemental New Drug Application for CAPLYTA®, aiming to prevent schizophrenia relapse, marking a significant step in expanding its mental health portfolio. Over the last quarter, Johnson & Johnson's stock price increased by 4%. This movement aligns with the broader market trends, which have shown steady growth despite some trade uncertainties. The company's efforts in the pharmaceutical sector and robust earnings likely contributed positively to its...
📄 Summary
Johnson & Johnson (NYSE:JNJ) submitted a supplemental New Drug Application for CAPLYTA®, aiming to prevent schizophrenia relapse, marking a significant step in expanding its mental health portfolio. Over the last quarter, Johnson & Johnson's stock price increased by 4%. This movement aligns with the broader market trends, which have shown steady growth despite some trade uncertainties. The company's efforts in the pharmaceutical sector and robust earnings likely contributed positively to its...